In order to gain insight into the biology of these poor prognosis ER+/HER2- breast cancers, we analyzed a public gene expression data set of early stage ER+ breast cancers treated with tamoxifen using a novel method. This evidence concerns the gene ERBB2 and breast carcinoma.